Acute deep vein thrombosis (DVT): evolving treatment strategies and endovascular therapy

Area of Science:

• Cardiovascular Medicine
• Vascular Surgery
• Interventional Radiology

Background:

• Deep vein thrombosis (DVT) and pulmonary embolism (PE) are significant causes of mortality, contributing to over 100,000 deaths annually.
• A substantial percentage of PE patients develop chronic thromboembolic pulmonary hypertension (CTEPH) (4%), and nearly 30% experience post-thrombotic syndrome (PTS).
• Standard anticoagulation is often insufficient in preventing PTS, highlighting the need for advanced therapeutic approaches.

Purpose of the Study:

• To evaluate the efficacy of pharmacomechanical catheter-directed thrombolysis (PCDT) in preventing PTS following proximal DVT.
• To compare outcomes of PCDT plus anticoagulation against anticoagulation alone in DVT patients.
• To contribute significant data to the understanding and management of DVT complications.

Main Methods:

• The ATTRACT trial, sponsored by NIH/NHLBI, is a randomized controlled trial.
• It compares patients receiving PCDT and standard anticoagulation versus those receiving standard anticoagulation only.
• Participants are individuals diagnosed with proximal DVT, enrolled at Miriam and RI Hospitals.

Main Results:

• The ATTRACT trial is ongoing and has not yet reported definitive results.
• Preliminary data and future findings are anticipated to provide critical insights into DVT management.
• The study aims to establish whether PCDT offers a significant advantage over anticoagulation alone.

Conclusions:

• Current anticoagulation strategies show limitations in preventing severe PTS.
• Emerging treatments like PCDT hold promise for mitigating the long-term consequences of DVT.
• The ATTRACT trial's results are expected to influence future clinical practice for DVT patients.